What You Should Know:
- Change Healthcare announced a new online COVID-19 research database to track disease progression, treatment efficacy, for qualified public and private healthcare organizations using de-identified data to understand disease progression and improve intervention.
- Actionable insight “beyond the diagnosis” enables health researchers to better understand COVID-19 progression, intervention effectiveness, and impacts on the healthcare system.
Today
Read More
Biopharma | News, Analysis, Insights - HIT Consultant
BrightInsight, CSL Behring Form Global Digital Health Partnership
What You Should Know:
- CSL Behring selects the BrightInsight Platform to build and manage its digital health solutions within a regulatory-compliant environment.
- The digital health partnership extends across therapeutic areas, including immunology, hematology and respiratory, among others.
BrightInsight,
Inc., a provider of the regulated IoT platform for biopharma and medtech,
and CSL Behring, a leading
biotechnology company, announced a global digital health partnership
Read More
AstraZeneca Selects BrightInsight’s IoT Platform to Focus on Chronic Disease Management
What You Should Know:
- AstraZeneca selects the BrightInsight Platform to build and manage its digital health solutions within a regulatory-compliant environment
- Digital health represents a major opportunity to alleviate some of the biggest concerns in healthcare today—many of which are being amplified due to COVID 19—including the length and cost of clinical trials, better remote testing, and tracking of patients, access to data and delivery of care.
- AstraZeneca and others are
Read More
Life Image, Graticule Launches Imaging Dataset In AWS Data Exchange
- Life Image and Graticule announced the availability of GLIMPS (Graticule Life Image Machine Parsed Set) data licensing subscriptions in AWS Data Exchange. - GLIMPS (Graticule Life Image Machine Parsed Set) is a de-identified patient-level data set including a summary of features generated from NLP processing on Life Image data. - The goal of GLIMPS is to provide a cost-effective patient-level snapshot to biopharma data science teams to fuel the necessary discussions about these data, leading
Read More
Life Image, Graticule Partner to Help Biopharma Accelerate Drug Development
- Life Image partners with Graticule to help biopharma realize the full potential of advanced data in real-world evidence programs.
- Partnership combines Life Image’s global medical evidence network specializing in imaging data with Graticule’s deep expertise applying advanced data to high-value use cases.
Life Image, the world’s largest medical evidence network for clinical and imaging data has announced a new partnership with Graticule to help life sciences companies accelerate drug
Read More
BrightInsight Nabs $25M for Regulated IoT Platform for Biopharma and Medtech
- BrightInsight raises $25M in Series A funding co-led by New Leaf Venture Partners and Eclipse Ventures to further enhance the functionality of its BrightInsight Platform and accelerate global commercialization efforts.
- BrightInsight platform enables regulated drugs, devices and SaMDs to ingest and analyze data and deploy regulated recommendations and insights back to patients and providers
BrightInsight, San Jose, CA-based global regulated digital health platform for biopharma and
Read More
Clinical Operations Makes Highest Use of Artificial Intelligence, Tufts Study Finds
Clinical operations function makes the highest use of artificial intelligence (AI) (61%), followed by pharmacovigilance/safety/risk management (57%), and information technology (IT) (55%), according to an analysis recently completed by the Tufts Center for the Study of Drug Development. The analysis, summarized in the May/June Tufts CSDD Impact Report, reveals the pharmaceutical industry is adopting artificial intelligence (AI) on numerous fronts, from discovery and clinical development to risk
Read More
Accenture: How New Science is Reshaping The Biopharma Landscape
Accenture has released new research that unveils strong evidence that the biopharma industry is facing compressive disruption when a series of innovations, macroeconomic factors, and other changes combine to squeeze profits over a decade or more. However, it also unveils a powerful growth engine: an emerging category that Accenture calls 'New Science' that is expected to drive 54% of the biopharma industry’s growth through 2022.
What is New Science?
New Science is an evolving, unique
Read More
